1. Clinical Microbiology and Infection
New dosing strategies for liposomal amphotericin B in high-risk patients 
Michael Ellis 
Clinical Microbiology and Infection 
Volume 14, Pages (May 2008)
DOI: /j x
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
(a) Amphotericin B concentration in lungs after one or four doses of LAB. (b) Fungal burden in lung tissue in mice infected with Aspergillus fumigatus treated for 3 days.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
(a) Concentrations of amphotericin B in kidney of immunosuppressed mice. (b) Concentrations of amphotericin B in spleen of immunosuppressed mice.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3
(a) Amphotericin B concentration in spleen. (b) Log10 CFU/g kidney at 6 weeks post-treatment.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

5. Fig. 4 Fungal burden in kidney.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

6. Fig. 5
High β-D-glucan levels in a patient without invasive fungal infection.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

7. Fig. 6 Bone marrow concentrations of amphotercin B.
Clinical Microbiology and Infection  , 55-64DOI: ( /j x)
Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions